Physician profile
Deborah Berry
NPI 1811267529
$1,471.66
in general payments reported to CMS, 2019-2025
18 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $311 · 2023: $257 · 2024: $147 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.15 | 2021-2025 | |
| Lilly USA, LLC | $182.11 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $137.84 | 2021-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.04 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $87.72 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $46.49 | 2021 | |
| Amarin Pharma, INC. | $45.38 | 2021 | |
| Avanir Pharmaceuticals, INC. | $34.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.72 | 2021 | |
| Abbott Laboratories | $19.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.63 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $16.56 | 2022 | |
| Pfizer INC. | $16.17 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.03 | 2021 | |
| Amgen INC. | $15.63 | 2021 | |
| Astellas Pharma US INC | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.